- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT02650401
Исследование энтректиниба (Rxdx-101) у детей и подростков с местнораспространенными или метастатическими солидными или первичными опухолями ЦНС и/или у которых нет удовлетворительных вариантов лечения (STARTRK-NG)
Фаза 1/2, открытое исследование с повышением дозы и увеличением дозы энтректиниба (Rxdx-101) в педиатрии с местнораспространенными или метастатическими солидными или первичными опухолями ЦНС и/или у которых нет удовлетворительных вариантов лечения
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Германия, 69120
- Universitaetsklinikum Heidelberg
-
-
-
-
-
Hong Kong, Гонконг, 00000
- Hong Kong Children's Hospital
-
-
-
-
-
Madrid, Испания, 28009
- Hospital Infantil Universitario Nino Jesus
-
-
-
-
Lombardy
-
Milan, Lombardy, Италия, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
-
-
Ontario
-
Toronto, Ontario, Канада, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Beijing, Китай
- Beijing Children's Hospital, Capital Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200082
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
-
-
-
-
London, Соединенное Королевство, SW3 6JJ
- Royal Marsden Hospital (Sutton)
-
Newcastle upon Tyne, Соединенное Королевство, NE1 4LP
- Royal Victoria Infirmary
-
-
-
-
California
-
La Jolla, California, Соединенные Штаты, 92093-0706
- University of California San Diego
-
San Francisco, California, Соединенные Штаты, 94158
- UCSF Benioff Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Egleston Children's Hospital at Emory University Atlanta
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63110
- Washington University,St. Louis Children's Hospital
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Соединенные Штаты, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health & Science Uni
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, Соединенные Штаты, 38105
- St. Jude Children'S Research Hospital
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- Texas Children's Cancer and Hematology Center
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84113
- Primary Children's Hospital
-
-
-
-
-
Lyon, Франция, 69373
- Centre Leon Berard
-
Marseille, Франция, 13385
- Hôpital de la Timone, Oncologie Pédiatrique
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Disease status:
-
Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1
-
Phase 2 portion:
- Part B: Participants must have measurable or evaluable disease, as defined by RANO
- Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
- Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
- Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
-
-
Tumor type:
-
Phase 1 portion:
* Part A: Relapsed or refractory extracranial solid tumors
-
Phase 2 portion
- Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
- Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
-
-
Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
-
Archival tumor tissue from diagnosis or, preferably, at relapse
-
Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
-
Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
-
Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment
-
Adequate organ and neurologic function
-
Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.
-
For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug
Exclusion Criteria:
- Receiving other experimental therapy
- Known congenital long QT syndrome
- History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
- Known active infections
- Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
- Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
- Prior treatment with approved or investigational TRK or ROS1 inhibitors
- Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
- Patients with NB with bone marrow space-only disease
- Incomplete recovery from acute effects of any surgery prior to treatment.
- Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
- Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: Extracranial solid tumors harboring NTRK1/2/3,
Arm closed for further enrollment ROS1, ALK non-gene fusion molecular alterations Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Другие имена:
|
|
Активный компаратор: CNS tumors harboring- NTRK1/2/3, ROS1, ALK
Arm closed for further enrollment molecular alterations, including gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Другие имена:
|
|
Активный компаратор: Neuroblastoma
Arm closed for further enrollment Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Другие имена:
|
|
Активный компаратор: Non-neuroblastoma, extracranial solid tumors
Arm closed for further enrollment harboring - NTRK1/2/3, ROS1, ALK gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Другие имена:
|
|
Активный компаратор: Any participant unable to swallow capsules
Arm closed for further enrollment Any participant who otherwise meet all other eligibility criteria Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Другие имена:
|
|
Активный компаратор: Expansion: CNS tumors harboring NTRK1/2/3, ROS1
gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Другие имена:
|
|
Активный компаратор: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1
NTRK 1,2,3 and ROS1 fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Временное ограничение: Approximately 6 months
|
Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03) |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Временное ограничение: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Временное ограничение: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Временное ограничение: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Временное ограничение: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Cohort B: Objective Response Rate (ORR)
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR |
Approximately 6 months
|
|
Cohort D: ORR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR |
Approximately 6 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Временное ограничение: Approximately 24 months
|
AE, ECG and Labs assessed by NCI CTCAE v4.03 |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F1 Formulation
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using minitablets/F15
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F1 Formulation
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation given intact
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using minitablets/F15
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F1 Formulation
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation given intact
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using minitablets/F15
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F1 Formulation
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using minitablets/F15
Временное ограничение: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: CBR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: CBR
Временное ограничение: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Progression-free Survival (PFS)
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: PFS
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: PFS
Временное ограничение: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Overall Survival (OS)
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 |
Approximately 6 months
|
|
Cohort B or E: OS
Временное ограничение: Approximately 6 months
|
Assessed by RANO |
Approximately 6 months
|
|
Cohort A, D, or E: ORR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: ORR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: ORR
Временное ограничение: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Time to response (TTR)
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: TTR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: TTR
Временное ограничение: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Duration of Response (DOR)
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: DOR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: DOR
Временное ограничение: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Временное ограничение: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Clinical Trials, Hoffmann-La Roche
Публикации и полезные ссылки
Общие публикации
- Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оцененный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- Педиатрический
- Рецидив
- Огнеупорный
- Саркома Юинга
- Медуллобластома
- Солидная опухоль
- Метастатический рак
- Саркома
- Нейробластома
- Папиллярный рак щитовидной железы
- Опухоли ЦНС
- РОС1
- НТРК
- АЛК
- Опухоли головного мозга
- НТРК1
- НТРК2
- НТРК3
- ТРК
- Тирозинкиназа
- Генная перестройка
- Детская фибросаркома
- Секреторный рак молочной железы
- Врожденная мезобластная нефрома
- Глиома моста
- Глиальные опухоли
- Рак слюнной железы (MASC)
- Опухоль Вильмса (анапластическая)
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Заболевания эндокринной системы
- Заболевания полости рта
- Стоматогнатические заболевания
- Заболевания головного мозга
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Патологические процессы
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Мужские мочеполовые заболевания
- Заболевания почек
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Атрибуты болезни
- Генетические заболевания, врожденные
- Новообразования по гистологическому типу
- Новообразования щитовидной железы
- Новообразования эндокринных желез
- Новообразования головы и шеи
- Новообразования железистые и эпителиальные
- Аденокарцинома
- Неопластические процессы
- Урологические новообразования
- Карцинома
- Новообразования, нейроэпителиальные
- Нейроэктодермальные опухоли
- Новообразования, зародышевые клетки и эмбриональные
- Новообразования, нервная ткань
- Новообразования нервной системы
- Новообразования почек
- Заболевания слюнных желез
- Неопластические синдромы, наследственные
- Новообразования соединительной и мягкой ткани
- Нейроэктодермальные опухоли, примитивные, периферические
- Нейроэктодермальные опухоли, примитивные
- Остеосаркома
- Новообразования, костная ткань
- Новообразования соединительной ткани
- Новообразования сложные и смешанные
- Заболевания щитовидной железы
- Аденокарцинома, папиллярная
- Рот Новообразования
- Врожденные, наследственные и неонатальные заболевания и аномалии
- Патологические состояния, признаки и симптомы
- Рак щитовидной железы, папиллярный
- Повторение
- Метастаз новообразования
- Глиома
- Нейробластома
- Саркома, Юинг
- Саркома
- Новообразования головного мозга
- Новообразования центральной нервной системы
- Медуллобластома
- Опухоль Вильмса
- Нефрома, мезобластная
- Новообразования слюнных желез
- Entrectinib
Другие идентификационные номера исследования
- RXDX-101-03
- CO40778 (Другой идентификатор: Hoffmann-La Roche)
- 2023-505088-35-00 (Ктис)
- 2023 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .